Back to search

Spain· ES:1262040003

JASCAYD 9 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

A medicinal product containing nerandomilast, registered in Spain by Boehringer Ingelheim International Gmbh.

Checked against AEMPS CIMA (Spain) on

Informational only — not a medical device.

SOURCE REGISTER · ESAEMPS CIMA (Spain)normalisedJASCAYD 9 MG COMPRIMIDOS RECUBIERTOS …ATC—REGISTER NO.ES:1262040003PACKS LISTED0CHECKEDJuly 27, 2026

The record

At a glance

AEMPS CIMA (Spain)
Active substance
nerandomilast
Manufacturer
Boehringer Ingelheim International Gmbh
Country
Spain (ES)
ATC code
—
Reimbursed
Not published by this register
Source register
AEMPS CIMA (Spain)
Last checked
July 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5e5abb19-5239-4770-be01-15bbb02516a5
GET /v1/drugs/5e5abb19-5239-4770-be01-15bbb02516a5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cpresc": "Uso Hospitalario",
  "estado": "{\"aut\":1784805240000}",
  "nregistro": "1262040003",
  "substance": "nerandomilast"
}

See everything about nerandomilast.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.